Display options
Cite
Walker S, Dresser L, Becker D, et al. An assessment of linezolid utilization in selected canadian provinces. Can J Infect Dis Med Microbiol. 2006;17(3):177-82doi: 10.1155/2006/818535.
Walker, S., Dresser, L., Becker, D., & Scalera, A. (2006). An assessment of linezolid utilization in selected canadian provinces. The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 17(3), 177-82. https://doi.org/10.1155/2006/818535
Walker, Sandra, et al. "An assessment of linezolid utilization in selected canadian provinces." The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale vol. 17,3 (2006): 177-82. doi: https://doi.org/10.1155/2006/818535
Walker S, Dresser L, Becker D, Scalera A. An assessment of linezolid utilization in selected canadian provinces. Can J Infect Dis Med Microbiol. 2006 May;17(3):177-82. doi: 10.1155/2006/818535. PMID: 18418496; PMCID: PMC2095071.
Copy Download .nbib Format: NLM
Share it on

Can J Infect Dis Med Microbiol. 2006 May;17(3):177-82. doi: 10.1155/2006/818535.

An assessment of linezolid utilization in selected canadian provinces.

The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale

Sandra Walker, Linda Dresser, Debbie Becker, Alissa Scalera

Affiliations

  1. Department of Pharmacy.

PMID: 18418496 PMCID: PMC2095071 DOI: 10.1155/2006/818535

Abstract

BACKGROUND: Linezolid is approved for the treatment of designated infections caused by methicillin-resistant and -susceptible Staphylococcus aureus and vancomycin-resistant Enterococcus faecium.

OBJECTIVE: To characterize linezolid utilization since its launch in Canada in 2001.

METHODS: Demographics, antimicrobial regimens, and clinical and resource utilization data for linezolid-treated patients were collected retrospectively by hospital pharmacists at nine tertiary care hospitals in four provinces. Statistics describing linezolid utilization were calculated and the appropriateness of use was assessed according to a treatment algorithm based on recommendations of the Infectious Diseases Pharmacy Specialty Network in 2001.

RESULTS: Ninety-nine linezolid courses were prescribed for 103 infections in 95 patients (mean age 57.8 years, 52.6% male) with an average length of hospital stay of 40.6 days. Fifty-three per cent of patients had an allergy to at least one antibiotic other than linezolid. The major use of linezolid was for treatment of skin and soft tissue infections (32.0%), followed by bacteremia (15.5%). The most prevalent pathogen was methicillin-resistant S aureus, identified in 44.7% of infections. Linezolid was primarily prescribed as the oral form following other intravenous anti-infectives (55.6% of courses) for an average duration of 14.4 days. The rate of appropriate utilization was 53% (range 25% to 75% by site). In 93.5% of courses deemed inappropriate, recommended first-line therapies were not attempted before linezolid.

CONCLUSIONS: Linezolid was prescribed appropriately in approximately one-half of cases reviewed. The rate of appropriate utilization is similar to those rates reported in other Canadian antibiotic reviews.

Keywords: Drug utilization; Linezolid; Staphylococcus aureus

References

  1. Pharmacoeconomics. 1994;5(Suppl 2):20-6 - PubMed
  2. Pharmacotherapy. 2001 Mar;21(3):263-74 - PubMed
  3. Am J Hosp Pharm. 1989 Jul;46(7):1385-9 - PubMed
  4. Can Fam Physician. 2000 Apr;46:851-9 - PubMed
  5. CMAJ. 2001 Jul 10;165(1):21-6 - PubMed
  6. Can J Hosp Pharm. 1990 Oct;43(5):221-5, xxxii - PubMed
  7. Ann Pharmacother. 1997 May;31(5):564-70 - PubMed
  8. Trends Microbiol. 1997 May;5(5):196-200 - PubMed
  9. Int J Antimicrob Agents. 2004 Feb;23(2):113-9 - PubMed
  10. Diagn Microbiol Infect Dis. 2002 May;43(1):75-83 - PubMed
  11. Can J Hosp Pharm. 1995 Feb;48(1):35-42 - PubMed
  12. Can J Hosp Pharm. 1991 Apr;44(2):83-7 - PubMed
  13. Drugs. 2001;61(4):525-51 - PubMed
  14. Can J Hosp Pharm. 1989 Aug;42(4):153-6 - PubMed
  15. Can J Hosp Pharm. 1994 Apr;47(2):59-64 - PubMed
  16. Can J Hosp Pharm. 1994 Apr;47(2):53-8 - PubMed
  17. Can J Hosp Pharm. 1994 Jun;47(3):111-6 - PubMed
  18. Can J Hosp Pharm. 1989 Apr;42(2):69-71 - PubMed

Publication Types